Loading clinical trials...
Loading clinical trials...
Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20
Conditions
Interventions
Azithromycin / Ivermectin / Ribaroxaban / Paracetamol
Azithromycin / Ribaroxaban / Paracetamol
Locations
1
Mexico
Alma Italia Guerrero Martinez
Mexico City, Mexico City, Mexico
Start Date
December 16, 2020
Primary Completion Date
February 25, 2021
Completion Date
February 25, 2021
Last Updated
August 16, 2021
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
Gilberto Cruz Arteaga
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions